Obeticholic acid (OCA), a potent and selective FXR agonist (Pellicciari et al., 2002), is a Food and Drug Administration-approved therapy for primary biliary cholangitis and is a promising drug for NAFLD (Chapman and Lynch, 2020). This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatotic liver disease.